Pharmaceuticals - France

  • France
  • The Pharmaceuticals market in France is expected to reach a revenue of US$27.30bn by 2024.
  • Among the various markets, Oncology Drugs is projected to be the largest, with a market volume of US$4.76bn in 2024.
  • The industry is anticipated to experience a steady annual growth rate of 3.99% (CAGR 2024-2029), resulting in a market volume of US$33.20bn by 2029.
  • When compared globally, United States is forecasted to generate the highest revenue, amounting to US$630.30bn in 2024.
  • France's pharmaceutical market is seeing an increase in government regulations, leading to tighter restrictions on drug pricing and reimbursement.

Key regions: United States, China, Germany, Japan, Europe

Region comparison

Analyst Opinion

France is one of the world's largest pharmaceutical markets, with a strong focus on research and development. In fact, France is home to some of the biggest pharmaceutical companies in the world.

Customer preferences:
French consumers tend to prefer branded drugs over generic ones, as they perceive them to be of higher quality. This has led to a higher market share for branded drugs in France compared to other European countries. Additionally, there is a growing trend towards natural and alternative medicines, which has led to an increase in demand for products in this category.

Trends in the market:
One of the major trends in the French pharmaceutical market is the increasing focus on innovation and research and development. French companies are investing heavily in developing new drugs and therapies, particularly in areas such as oncology, immunology, and rare diseases. Another trend is the growing importance of digital technologies in healthcare, which is leading to the development of new products and services in this area.

Local special circumstances:
France has a highly regulated pharmaceutical market, with strict pricing controls and reimbursement policies. This can make it challenging for companies to enter the market, but it also ensures that drugs are accessible to all French citizens. Additionally, France has a strong tradition of public healthcare, which means that the government plays a significant role in shaping the pharmaceutical market.

Underlying macroeconomic factors:
The French pharmaceutical market is influenced by a range of macroeconomic factors, including demographic changes, healthcare spending, and government policies. For example, an aging population is driving demand for drugs and healthcare services, while healthcare spending is under pressure due to budget constraints. Government policies, such as pricing controls and reimbursement policies, also have a significant impact on the market. Overall, the French pharmaceutical market is likely to continue to grow in the coming years, driven by innovation, changing consumer preferences, and underlying macroeconomic factors.


Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.


In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.


  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait


Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)